Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.160
-0.010 (-0.85%)
May 27, 2025, 3:06 PM - Market open
Acrivon Therapeutics Stock Forecast
ACRV's stock price has decreased by -86.35% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Acrivon Therapeutics stock ranges from a low of $9.00 to a high of $27. The average analyst price target of $17.6 forecasts a 1,417.24% increase in the stock price over the next year.
Price Target: $17.60 (+1,417.24%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Acrivon Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 16, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +675.86% | May 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +1,537.93% | Mar 28, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Mar 26, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $17 | Buy | Reiterates | $17 | +1,365.52% | Mar 26, 2025 |
Financial Forecast
Revenue This Year
n/a
from 113.90M
Revenue Next Year
n/a
EPS This Year
-2.45
from -2.38
EPS Next Year
-2.56
from -2.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.2M | 11.0M | 45.1M | ||
| Avg | 147,900 | 1.8M | 9.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -98.9% | 7,354.4% | 2,427.6% | ||
| Avg | -99.9% | 1,106.9% | 420.7% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.21 | -2.14 | -1.88 | ||
| Avg | -2.45 | -2.56 | -2.55 | ||
| Low | -2.84 | -3.43 | -3.97 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.